Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
Trial details
- Registry ID
- NCT01115582
- Phase
- Phase 3
The FDA approved Cholic acid on 17 Mar 2015.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisNCT01115582 | MIRM | Phase 3 | Completed | 2010-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2015-03-17Day | Cholic acid | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA205750", "applicant_as_listed_by_fda": "MIRUM", "brand_names": ["CHOLBAM"], "active_ingredients": ["CHOLIC ACID"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20150317", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |